Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Peter Clark, MA, MD, FRCP: A Payer Perspective

Jul

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Peter Clark, MA, MD, FRCP: A Payer Perspective

AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms

Multiple Myeloma Studies Highlight Advances Across the Field

Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma

Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?

Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer